New data from the TRACTION trial provides compelling evidence of tranexamic acid’s clinical impact. The study documented 127 major bleeding events per 1,000 patients in the placebo group, compared to just 89 events in the tranexamic acid group—preventing 38 serious bleeding complications per 1,000 surgical patients treated.
This substantial protective effect carries particular significance given the drug’s accessibility and cost-effectiveness. The intervention represents a straightforward addition to standard surgical protocols, with no increase in clotting-related adverse events observed among the 9,535 participants across 29 countries. For healthcare systems globally, these numbers translate to meaningful reductions in patient morbidity, transfusion requirements, and associated complications, making tranexamic acid a high-impact tool for improving surgical safety outcomes.
Read the full article on GMJ Newsroom.
Was this article helpful?
